Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2025
Survival Outcomes in Cutaneous Angiosarcoma: A Meta Analysis.
СтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Patel Aneri Bhargav, Driscoll William, Sharma Ajay Nair, Horton Luke, Smith Janellen
Аннотация
BACKGROUND: Cutaneous angiosarcoma is a rare, aggressive malignancy with a poor prognosis and limited evidence guiding treatment. Optimal therapy remains undefined due to disease heterogeneity and a lack of large prospective trials.
OBJECTIVE: To assess survival outcomes across treatment modalities and clinical stages in patients with angiosarcoma using a meta-analysis.
METHODS: A systematic search identified studies reporting treatment and outcome data for cutaneous angiosarcoma. Patient-level data from 159 patients across 9 studies were extracted. Patients were stratified into early-stage and mid/late-stage. Statistical analyses included Kaplan-Meier estimates, Cox regression, and subgroup comparisons of recurrence, metastasis, and survival.
RESULTS: Early-stage patients showed longer average survival-as well as delayed recurrence and metastasis-compared with mid/late-stage patients; differences were not statistically significant. Tumor location was the strongest predictor of survival in advanced-stage disease, while age predicted mortality in early-stage, with younger patients having improved survival. Treatment modality and surgical type were not independently associated with survival.
CONCLUSION: Tumor location and patient age are important prognostic factors in angiosarcoma. Treatment modality did not significantly affect survival or recurrence, supporting individualized treatment and further investigation into survival determinants.
OBJECTIVE: To assess survival outcomes across treatment modalities and clinical stages in patients with angiosarcoma using a meta-analysis.
METHODS: A systematic search identified studies reporting treatment and outcome data for cutaneous angiosarcoma. Patient-level data from 159 patients across 9 studies were extracted. Patients were stratified into early-stage and mid/late-stage. Statistical analyses included Kaplan-Meier estimates, Cox regression, and subgroup comparisons of recurrence, metastasis, and survival.
RESULTS: Early-stage patients showed longer average survival-as well as delayed recurrence and metastasis-compared with mid/late-stage patients; differences were not statistically significant. Tumor location was the strongest predictor of survival in advanced-stage disease, while age predicted mortality in early-stage, with younger patients having improved survival. Treatment modality and surgical type were not independently associated with survival.
CONCLUSION: Tumor location and patient age are important prognostic factors in angiosarcoma. Treatment modality did not significantly affect survival or recurrence, supporting individualized treatment and further investigation into survival determinants.